Cargando…

Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy

BACKGROUND: Stromal tumor-infiltrating lymphocytes (sTILs) have been identified as a predictive biomarker for response to neoadjuvant chemotherapy (NAC) and prognosis in human epidermal growth factor receptor 2 (HER2)-positive breast cancers. However, standardized scoring methods for use in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xia, Rao, Jia, Yang, Wentao, Shui, Ruohong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297199/ https://www.ncbi.nlm.nih.gov/pubmed/30406444 http://dx.doi.org/10.1007/s11523-018-0602-1

Ejemplares similares

Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
por: Ruan, Miao, et al.
Publicado: (2018)

Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers
por: Tian, Tian, et al.
Publicado: (2016)

Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis
por: Li, Shiqi, et al.
Publicado: (2022)

Prognostic value of extranodal extension in axillary lymph node-positive breast cancer
por: Ma, XiaoXi, et al.
Publicado: (2021)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes
por: Liu, Shiwei, et al.
Publicado: (2020)

A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
por: Hamy, Anne-Sophie, et al.
Publicado: (2016)

Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Herrero-Vicent, Carmen, et al.
Publicado: (2017)

Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy
por: Liu, Jiawei, et al.
Publicado: (2019)

Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
por: Ma, Youzhao, et al.
Publicado: (2023)

Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer
por: Brodsky, Alexander S., et al.
Publicado: (2016)

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression
por: Shang, Mao, et al.
Publicado: (2022)

Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab
por: Honkanen, Tiia J., et al.
Publicado: (2017)

Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy
por: Bai, Yu-Ge, et al.
Publicado: (2020)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
por: Cai, Mengyuan, et al.
Publicado: (2023)

Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2−Negative Postmenopausal Breast Cancer Patients
por: Pousette, Jenny, et al.
Publicado: (2022)

Assessment of Intratumoural and Stromal Infiltrating Lymphocytes in the Various Subtypes of Breast Carcinoma Patients who have Received Neoadjuvant Chemotherapy
por: Rangan, Rahul, et al.
Publicado: (2023)

Prognostic Value of Tumor Infiltrating Lymphocytes in Locally Advanced HER2 Enriched Breast Cancer
por: Saber, Mostafa M, et al.
Publicado: (2022)

The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Van Berckelaer, Christophe, et al.
Publicado: (2021)

The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer
por: Li, Jun, et al.
Publicado: (2017)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Clinical significance of extranodal extension in sentinel lymph node positive breast cancer
por: Yang, Xia, et al.
Publicado: (2020)

Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy
por: Huang, Liang, et al.
Publicado: (2013)

The Predictive and Prognostic Role of Stromal Tumor-infiltrating Lymphocytes in HER2-positive Breast Cancer with Trastuzumab-based Treatment: a Meta-analysis and Systematic Review
por: Xu, Tao, et al.
Publicado: (2017)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
por: Liontos, M., et al.
Publicado: (2021)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
por: Li, Si, et al.
Publicado: (2018)

The Value of Tumor Infiltrating Lymphocytes (TIL) for Predicting the Response to Neoadjuvant Chemotherapy (NAC) in Breast Cancer according to the Molecular Subtypes
por: Faur, Ionut Flaviu, et al.
Publicado: (2023)

The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis
por: Zhang, Wei, et al.
Publicado: (2017)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer
por: Zhao, Chaohui Lisa, et al.
Publicado: (2019)

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature
por: Isca, Chrystel, et al.
Publicado: (2021)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis
por: Mao, Yan, et al.
Publicado: (2014)

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
por: Hida, Akira I., et al.
Publicado: (2016)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
por: Maibach, Fabienne, et al.
Publicado: (2020)

Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis
por: Qi, Xue, et al.
Publicado: (2023)

Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
por: Yang, Libo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2i8hp3dvibluc0i4smur3obivu